Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 5, 2010, Pages 503-509

  Aoki, Orgnamechie ^a   Hattori, Yoshiyuki ^a   Tomizawa, Atsuko ^a   Jojima, Teruo ^a   Kasai, Kikuo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Ampk; Camp; Inflammation; Nf b; Vascular smooth muscle

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; CILOSTAZOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN KINASE P60; PROTEIN P50; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 77953335543     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3392     Document Type: Article

References (14)

1. Goto S: Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler, 2005 (Suppl); 6: 3-11
2. Suzuki K, Uchida K, Nakanishi N, Hattori Y: Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens, 2008; 21: 451-457
3. Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S, Satoh H, Akimoto K, Kasai K: Cilostazol inhibits cytokine-induced nuclear factor-{kappa}B activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res, 2009; 81: 133-139
4. Camley-Cambell J, Campbell GR, Ross R: The smoth muscle in culture. Physiol Rev, 1979; 59: 1-61
5. Hattori Y, Suzuki M, Hattori S, Kasai, K: Vascular smooth muscle cell activation by glycated albumin (Amadoriadducts). Hypertension, 2002; 39: 22-28
6. Hattori Y, Kasai K, Gross SS: NO suppresses while peroxynitrite sustains NF-kB: A paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res, 2004; 63: 31-40
7. Hattori Y, Gross SS: GTP cyclohydrolase mRNA is induceds by LPS invascular smooth muscle: characterization, sequence and relationship to nitric oxide synthase. Biochem Biophys Res Commun, 1993; 195: 435-441.
8. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I: 5-aminoimidazole-4-carboxamide-1- beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci, 2004; 24: 479-487
9. Hardie DG: The AMP-activated protein kinase pathway new players upstream and downstream. J Cell Sci, 2004; 117: 5479-5487
10. Dagher Z, Ruderman N, Tornheim K, Ido Y: Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ Res, 2001; 88: 1276-1282
11. Gotoh F, Tohgi H, Hirai S1, Terashi A, Fukuuchi Y: Cilostazol stroke prevention study: a placebo-controlled doubleblinded trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis, 2000; 9: 147-157
12. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique anti-thrombotic agent. Curr Pharm Des, 2003; 9: 2289-2302
13. Iwamoto T, Kin K, Miyazaki K, Shin K, Takasaki M: Recovery of platelet function after withdrawal of cilostazol administered orally for a long period. J Atheroscler Thromb, 2003; 10: 348-354
14. Oida K, Ebata K, Kanehara H, Suzuki J, Miyamori I: Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. J Atheroscler Thromb, 2003; 10: 93-98.